Phase 3Active, not recruiting
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
- Sponsor
- EyePoint Pharmaceuticals, Inc. (Industry)
- Enrolment
- 240 planned
- Conditions
- Diabetic Macular Edema; DME; Diabetic Macular Edema (DME)
- Interventions
- EYP-1901; Aflibercept (2.0 mg)
- Ages
- adults, older adults
- Registry
- NCT07449923
From the registry
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Primary outcomes
- Average change in best corrected visual acuity (BCVA)